This Article Full Text Full Text (PDF) CME: Take the course for this article: Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coleman, R. L. Search for Related Content PubMed PubMed Citation Articles by Coleman, R. L.

Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary

University of Texas, Southwestern Medical Center, Dallas, Texas, USA

Correspondence: Robert L. Coleman, M.D., Associate Professor of Obstetrics and Gynecology, University of Texas, Southwestern Medical Center, 5323 Harry Hines Boulevard, Building J7.124, Dallas, Texas 75390-9032, USA. Telephone: 214-648-3026; Fax: 214-648-8404; e-mail: Robert.Coleman{at}UTSouthwestern.edu

The conventional front-line chemotherapy strategy for advanced epithelial ovarian carcinoma has become adjuvant administration of platinum (carboplatin and cisplatin), either alone or, most often, in combination with a taxane. However, a number of active agents have been identified in phase II/III trials of second-line and salvage ovarian cancer patients that may augment this front-line strategy. One agent, topotecan, has antitumor activity comparable with paclitaxel in patients with recurrent ovarian cancer and is an established treatment in second-line or salvage settings. Additionally, its mechanism of action is different from paclitaxel and is nonoverlapping. These properties, coupled with the in vitro synergy observed in tumor models among topotecan, paclitaxel, and platinum, have provided the rationale for investigators to examine topotecan in front-line ovarian cancer therapy. A number of strategies for incorporating topotecan into front-line therapy are under active investigation, including the replacement of paclitaxel with topotecan, a triplet regimen with cisplatin or carboplatin and paclitaxel, a consolidation regimen consisting of several courses of a platinum agent and paclitaxel followed by several courses of topotecan, and a sequential doublet regimen in which patients receive platinum in every course as part of a doublet with alternating or sequential topotecan and paclitaxel. Preliminary data from ongoing clinical trials of these new regimens show favorable response rates and generally manageable toxicity profiles. This review summarizes the preliminary clinical findings associated with the four strategies and outlines ongoing and future randomized studies of topotecan in front-line ovarian cancer.

Key Words. Carboplatin • Cisplatin • Neutropenia • Ovarian neoplasms • Paclitaxel • Topotecan

This article has been cited by other articles:

				C. D. Pond, K. M. Marshall, and L. R. Barrows Identification of a small topoisomerase I-binding peptide that has synergistic antitumor activity with 9-aminocamptothecin. Mol. Cancer Ther., March 1, 2006; 5(3): 739 - 745. [Abstract] [Full Text] [PDF]

				J. M. McLoughlin, T. M. McCarty, C. Cunningham, V. Clark, N. Senzer, J. Nemunaitis, and J. A. Kuhn TNFerade, an Adenovector Carrying the Transgene for Human Tumor Necrosis Factor {alpha}, for Patients With Advanced Solid Tumors: Surgical Experience and Long-Term Follow-Up Ann. Surg. Oncol., October 1, 2005; 12(10): 825 - 830. [Abstract] [Full Text] [PDF]

				H. Wu, T. Han, N. Belousova, V. Krasnykh, E. Kashentseva, I. Dmitriev, M. Kataram, P. J. Mahasreshti, and D. T. Curiel Identification of Sites in Adenovirus Hexon for Foreign Peptide Incorporation J. Virol., March 15, 2005; 79(6): 3382 - 3390. [Abstract] [Full Text] [PDF]

				Q. Zhang, M. Nie, J. Sham, C. Su, H. Xue, D. Chua, W. Wang, Z. Cui, Y. Liu, C. Liu, et al. Effective Gene-Viral Therapy for Telomerase-Positive Cancers by Selective Replicative-Competent Adenovirus Combining with Endostatin Gene Cancer Res., August 1, 2004; 64(15): 5390 - 5397. [Abstract] [Full Text] [PDF]

				M. Rinne, D. Caldwell, and M. R. Kelley Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells Mol. Cancer Ther., August 1, 2004; 3(8): 955 - 967. [Abstract] [Full Text] [PDF]

				M.-Y. Cao, Y. Lee, N.-P. Feng, K. Xiong, H. Jin, M. Wang, A. Vassilakos, S. Viau, J. A. Wright, and A. H. Young Adenovirus-Mediated Ribonucleotide Reductase R1 Gene Therapy of Human Colon Adenocarcinoma Clin. Cancer Res., October 1, 2003; 9(12): 4553 - 4561. [Abstract] [Full Text] [PDF]